Literature DB >> 20709598

Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.

P R Donald1.   

Abstract

Tuberculous meningitis (TBM) causes a devastating morbidity and mortality in adults and children. Even in patients presenting at an early stage of disease, deterioration may occur despite apparently adequate therapy. The literature relating to cerebrospinal fluid penetration of antituberculosis agents is reviewed. Amongst the essential antituberculosis agents isoniazid has the best CSF pharmacokinetics reaching peak concentrations (C(max)) only slightly less than in blood. Pyrazinamide also has good CSF penetration and in children receiving dosages of 40 mg/kg the CSF C(max) exceeds the proposed minimal inhibitory concentration of 20 μg/ml. Streptomycin other aminoglycosides and ethambutol have poor CSF penetration and cannot be agents of first choice for TBM treatment. Rifampicin at dosages used in adults seldom reaches CSF concentrations exceeding MIC, but does so more frequently in children when dosages of up to 20 mg/kg are used. The non-essential agents ethionamide, the fluoroquinolones, with the exception of ciprofloxacin, and cycloserine (terizadone) have relatively good CSF penetration and are recommended for TBM treatment. The dosages of the essential agents recommended for the treatment of TBM in children are INH 10 mg/kg (range 6-15 mg/kg bodyweight), rifampicin 15 mg/kg (range 10-20 mg/kg), pyrazinamide 35 mg/kg (range 30-40 mg/kg), ethambutol 20 mg/kg (range 15-25 mg/kg) and streptomycin 15 mg/kg (range 12-18 mg/kg). Amongst second-line agents ofloxacin, levofloxacin and moxifloxacin should be used in dosages of 15-20 mg/kg, ethionamide 20 mg/kg in a single dose, if tolerated, and for cycloserine (terizadone) 15 mg/kg. Antituberculous chemotherapy should be started as soon as the diagnosis of TBM is considered.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709598     DOI: 10.1016/j.tube.2010.07.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  60 in total

1.  Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study.

Authors:  Christopher Vinnard; Liza King; Sonal Munsiff; Aldo Crossa; Kentaro Iwata; Jotam Pasipanodya; Douglas Proops; Shama Ahuja
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

2.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

3.  A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.

Authors:  Kaitlyn Schaaf; Samuel R Smith; Virginia Hayley; Olaf Kutsch; Jim Sun
Journal:  J Vis Exp       Date:  2017-03-24       Impact factor: 1.355

4.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Authors:  Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

5.  Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.

Authors:  Agibothu Kupparam Hemanth Kumar; Alok Kumar; Thiruvengadam Kannan; Rakesh Bhatia; Dipti Agarwal; Santosh Kumar; Rajeshwar Dayal; Sheo Pratap Singh; Geetha Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 6.  Advances in the Diagnosis and Management of Tubercular Meningitis in Children.

Authors:  Himani Bhasin; Medha Goyal; Suvasini Sharma
Journal:  Indian J Pediatr       Date:  2019-12-04       Impact factor: 1.967

7.  Neurological complications after tuberculous meningitis in a multi-state cohort in the United States.

Authors:  Alexander E Merkler; Alexandra S Reynolds; Gino Gialdini; Nicholas A Morris; Santosh B Murthy; Kiran Thakur; Hooman Kamel
Journal:  J Neurol Sci       Date:  2017-02-24       Impact factor: 3.181

8.  Key considerations in the pharmacotherapy of tuberculous meningitis.

Authors:  Sean Wasserman; Angharad Davis; Robert J Wilkinson; Graeme Meintjes
Journal:  Expert Opin Pharmacother       Date:  2019-07-15       Impact factor: 3.889

Review 9.  A 43-year systematic review and meta-analysis: case-fatality and risk of death among adults with tuberculous meningitis in Africa.

Authors:  Yohannes W Woldeamanuel; Belaineh Girma
Journal:  J Neurol       Date:  2013-08-21       Impact factor: 4.849

Review 10.  Understanding pharmacokinetics to improve tuberculosis treatment outcome.

Authors:  Jonathan Reynolds; Scott K Heysell
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-03-06       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.